Vilar-Gomez E, et al. - In patients with type 2 diabetes and non-alcoholic steatohepatitis, researchers ascertained if use of metformin long-term can improve survival and lower liver-related outcomes. Between October 2004 and January 2016 at the Indiana University Medical Center, a total of 191 diabetic patients with biopsy-proven non-alcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis were found retrospectively; of these, 110 were metformin users and 81 were never-users. According to results, 85% of metformin users and 88% of non-users had cirrhosis. In diabetics with non-alcoholic steatohepatitis and advanced fibrosis, the research showed a link between long-term use of metformin and decreased risk of all-cause mortality/transplantation and hepatocellular carcinoma. They did not see any cases of hepatotoxicity or lactic acidosis.